Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Morie A. Gertz, Rafat Abonour, Sarah N. Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany P. Quock, Cara A. Rosenbaum, Michael Rosenzweig, Surbhi Sidana, Sascha A. Tuchman, Ronald Witteles, Irina Yermilov, Michael S. Broder

Blood (2022) 140 (Supplement 1): 13129–13131.

https://doi.org/10.1182/blood-2022-156832

Published: 2022

Journal Articles

COVID-19 Pandemic Highlights Health Disparities in Latinos in San Diego

Elisa Quiroz, MD, David J Hermel, MD, Samantha R Bagsic, PhD, Carrie L. Costantini, MD, Anuj Mahindra, MD, Alan Saven, MD, Zhubin Gahvari, MD, Emily Nagler, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-143440

Published: 2020

Journal Articles

Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without

Anuj Mahindra, MD, Parmeswaran Hari, MD MRCP, MS, Raphael Fraser, PhD, Mingwei Fei, MS, Tomer Mark, MD, Yago Nieto, MD PhD, Anita D'Souza, MBBS, MD

Blood (2016) 128 (22): 994.

https://doi.org/10.1182/blood.V128.22.994.994

Published: 2016

Journal Articles

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Rachid C. Baz, Thomas G. Martin, III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina, Sundar Jagannath

Blood (2016) 127 (21): 2561–2568.

https://doi.org/10.1182/blood-2015-11-682518

Published: 2016

Includes: Supplemental data

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 303.

https://doi.org/10.1182/blood.V124.21.303.303

Published: 2014

Journal Articles

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

Claire C Greene, BA, Jimmy Hwang, PhD, Jeffrey Lee Wolf, MD, Lloyd E Damon, MD, Anuj Mahindra, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 3388.

https://doi.org/10.1182/blood.V122.21.3388.3388

Published: 2013

Journal Articles

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Rachid Baz, MD, Thomas G Martin, III, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel Sullivan, M.D., Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2013) 122 (21): 3200.

https://doi.org/10.1182/blood.V122.21.3200.3200

Published: 2013

Journal Articles

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Erica Evans, Juswinder Singh, Wes Westlin, Noopur Raje

Blood (2012) 120 (21): 1822.

https://doi.org/10.1182/blood.V120.21.1822.1822

Published: 2012

Journal Articles

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Loredana Santo, Diana Cirstea, Bin Wang, Tso-Pang Yao, Joy Y. Wu, Peter Waterman, Derrick Jeon, Mary Bouxsein, Leeann Louis, Sutada Lotinun, Roland Baron, Homare Eda, Neeharika Nemani, Anuj Mahindra, Andrew J. Yee, Teru Hideshima, Kenneth C. Anderson, Simon S Jones, Noopur Raje, MD

Blood (2012) 120 (21): 328.

https://doi.org/10.1182/blood.V120.21.328.328

Published: 2012

Journal Articles

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Tyler Scullen, Sonia Vallet, Loredana Santo, Mariateresa Fulciniti, PhD, Homare Eda, Diana D. Cirstea, MD, Kishan Patel, Andrew Yee, Anuj Mahindra, MD, Noopur Raje, MD

Blood (2012) 120 (21): 1871.

https://doi.org/10.1182/blood.V120.21.1871.1871

Published: 2012

Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Chirayu Patel, Andrew Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Anuj Mahindra, Paul G. Richardson, MD, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Kenneth C. Anderson, Nikhil C Munshi, MD, Noopur Raje

Blood (2012) 120 (21): 3965.

https://doi.org/10.1182/blood.V120.21.3965.3965

Published: 2012

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Sonia Vallet, Noopur Raje

Blood (2012) 120 (21): 3989.

https://doi.org/10.1182/blood.V120.21.3989.3989

Published: 2012

Journal Articles

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Anuj Mahindra, MD, Dora Dias-Santagata, Ph.D., Darrell Borger, Ph.D., Loredana Santo, Tyler A. Scullen, Andrew Yee, Homare Eda, Diana Cirstea, Anthony John Iafrate, M.D., Ph.D., Noopur Raje, MD

Blood (2012) 120 (21): 3990.

https://doi.org/10.1182/blood.V120.21.3990.3990

Published: 2012

Journal Articles

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Diana Cirstea, Teru Hideshima, MD, PhD, Loredana Santo, Homare Eda, Tyler A. Scullen, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Yiguo Hu, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M Guichard, Kenneth C. Anderson, Noopur Raje

Blood (2012) 120 (21): 4023.

https://doi.org/10.1182/blood.V120.21.4023.4023

Published: 2012

Journal Articles

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

Anuj Mahindra, Ayman A Saad, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Angela Dispenzieri, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Marcelo C Pasquini, MD, MS, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 4217.

https://doi.org/10.1182/blood.V120.21.4217.4217

Published: 2012

Journal Articles

Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Girindra Raval, Anuj Mahindra, MD, Xiaobo Zhong, MS, Ruta Brazauskas, PhD, Robert Peter Gale, MD, PhD, DSc, FACP, Nancy Brandenburg, PhD, Sagar Lonial, MD, Amrita Krishnan, MD, Angela Dispenzieri, MD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2012) 120 (21): 591.

https://doi.org/10.1182/blood.V120.21.591.591

Published: 2012

Journal Articles

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Diana Cirstea, Teru Hideshima, Loredana Santo, Samantha Pozzi, Sonia Vallet, Kishan Patel, Gullu Gorgun, Yiguo Hu, Sylvie M Guichard, Anuj Mahindra, Kenneth C. Anderson, Noopur Raje

Blood (2010) 116 (21): 791.

https://doi.org/10.1182/blood.V116.21.791.791

Published: 2010

Journal Articles

Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma

Anuj Mahindra, MD, Samir B. Amin, MBBS, Aliyah R. Sohani, MD, Gabriela Motyckova, MD, PhD, Kishan Patel, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, Diana Cirstea, M.D., Christiana E. Toomey, James S. Michaelson, PhD, Ephraim P. Hochberg, MD, Paola Dal Cin, PhD, Scott J Rodig, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi, MD, Noopur Raje, MD

Blood (2010) 116 (21): 4042.

https://doi.org/10.1182/blood.V116.21.4042.4042

Published: 2010

Journal Articles

Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy

Sonia Vallet, MD, Kishan Patel, Diana Cirstea, MD, Katie Luly, Samantha Pozzi, MD, Loredana Santo, MD, Homare Eda, MD, Jasbir Seehra, Anuj Mahindra, MD, David T. Scadden, MD, Noopur Raje, MD

Blood (2010) 116 (21): 4075.

https://doi.org/10.1182/blood.V116.21.4075.4075

Published: 2010

Journal Articles

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Blood (2010) 116 (21): 3051.

https://doi.org/10.1182/blood.V116.21.3051.3051

Published: 2010

NARROW

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

COVID-19 Pandemic Highlights Health Disparities in Latinos in San Diego

Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Autologous Transplantation Is Safe and Effective For Patients With Multiple Myeloma Related Renal Insufficiency

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease

Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells

Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma

Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only